Treatment options in Alzheimer's disease: Maximizing benefit, managing expectations

被引:103
作者
Farlow, Martin R. [1 ]
Miller, Michael L. [2 ]
Pejovic, Vojislav [2 ]
机构
[1] Indiana Univ, Sch Med, Dept Neurol, Indianapolis, IN 46202 USA
[2] Prescott Med Commun Grp, Chicago, IL USA
关键词
Alzheimer's disease; cholinesterase inhibitors; Memantine; pharmacotherapy; combination therapy; antioxidants; Ginkgo biloba;
D O I
10.1159/000122962
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Alzheimer's disease ( AD) is becoming an increasingly heavy burden on the society of developed countries, and physicians now face the challenge of providing efficient treatment regimens to an ever-higher number of individuals affected by the disease. Currently approved anti-AD therapies - the cholinesterase inhibitors and the N-methyl-D-aspartate receptor antagonist memantine-offer modest symptomatic relief, which can be enhanced using combination therapy with both classes of drugs. Additionally, alternative therapies such as nonsteroidal anti-inflammatory drugs, vitamin E, selegiline, Ginkgo biloba extracts, estrogens, and statins, as well as behavioral and lifestyle changes, have been explored as therapeutic options. Until a therapy is developed that can prevent or reverse the disease, the optimal goal for effective AD management is to develop a treatment regimen that will yield maximum benefits for individual patients across multiple domains, including cognition, daily functioning, and behavior, and to provide realistic expectations for patients and caregivers throughout the course of the disease. This review provides a basic overview of approved AD therapies, discusses some pharmacologic and nonpharmacologic treatment strategies that are currently being investigated, and offers suggestions for optimizing treatment to fit the needs of individual patients. Copyright (c) 2008 S. Karger AG, Basel.
引用
收藏
页码:408 / 422
页数:15
相关论文
共 182 条
  • [61] The effects of exercise training on elderly persons with cognitive impairment and dementia: A meta-analysis
    Heyn, P
    Abreu, BC
    Ottenbacher, KJ
    [J]. ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION, 2004, 85 (10): : 1694 - 1704
  • [62] Atypical antipsychotic medications and risk of falls in residents of aged care facilities
    Hien, LT
    Cumming, RG
    Cameron, ID
    Chen, JS
    Lord, SR
    March, LM
    Schwarz, J
    Le Couteur, DG
    Sambrook, PN
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2005, 53 (08) : 1290 - 1295
  • [63] Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease
    in 't Veld, BA
    Ruitenberg, A
    Hofman, A
    Launer, LJ
    van Duijn, CM
    Stijnen, T
    Breteler, MMB
    Stricker, BHC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (21) : 1515 - 1521
  • [64] Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain
    Ingelsson, M
    Fukumoto, H
    Newell, KL
    Growdon, JH
    Hedley-Whyte, ET
    Frosch, MP
    Albert, MS
    Hyman, BT
    Irizarry, MC
    [J]. NEUROLOGY, 2004, 62 (06) : 925 - 931
  • [65] Neuroticism and longitudinal change in caregiver depression: Impact of a spouse-caregiver intervention program
    Jang, Y
    Clay, OJ
    Roth, DL
    Haley, WE
    Mittelman, MS
    [J]. GERONTOLOGIST, 2004, 44 (03) : 311 - 317
  • [66] Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors
    Jann, MW
    Shirley, KL
    Small, GW
    [J]. CLINICAL PHARMACOKINETICS, 2002, 41 (10) : 719 - 739
  • [67] Clinical trials in mild cognitive impairment: lessons for the future
    Jelic, V
    Kivipelto, M
    Winblad, B
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2006, 77 (04) : 429 - 438
  • [68] Neuroimaging in Alzheimer disease: An evidence-based review
    Kantarci, K
    Jack, CR
    [J]. NEUROIMAGING CLINICS OF NORTH AMERICA, 2003, 13 (02) : 197 - +
  • [69] Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study
    Kivipelto, Miia
    Ngandu, Tiia
    Laatikainen, Tiina
    Winblad, Bengt
    Soininen, Hilkka
    Tuomilehto, Jaakko
    [J]. LANCET NEUROLOGY, 2006, 5 (09) : 735 - 741
  • [70] In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses
    Kuhl, DE
    Koeppe, RA
    Snyder, SE
    Minoshima, S
    Frey, KA
    Kilbourn, MR
    [J]. ANNALS OF NEUROLOGY, 2006, 59 (01) : 13 - 20